A Phase I Dose Finding Study of MB-CART2219.1
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Trial Details
- NCT ID
- NCT07108868
- Phase
- PHASE1
- Sponsor
- University Hospital Tuebingen
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- CAR-T cells targeting CD19 and CD22
- Locations (sample)
- Tübingen, Baden-Wurttemberg, Germany|48.52266,9.05222
- Tübingen, Baden-Wurttemberg, Germany|48.52266,9.05222
Key Eligibility Criteria
- For Cohort I Lymphoma, adults: Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- For Cohort II ALL, pediatrics: Subject is ≥ 12 years of age at the time of signing ICF.
- Patient or legal guardian understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
- Able to adhere to the study visit schedule and other protocol requirements as well as agrees to continued follow up for up to 15 years as mandated …
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →